Clostridium difficile infection is one of the most common healthcare-associated infections in adults in the United States. Older Americans are especially vulnerable to CDI, 2 and this infection has ...

Singulex’s Clarity C. diff toxin A/B assay, a rapid C. diff toxin test, has made its commercial debut, the company announced. “The Clarity toxin A/B assay offers a new approach to testing for C. diff ...

A new study, led by researchers from the University of California, Irvine (UCI), uncovers the long-sought-after, three-dimensional structure of a toxin primarily responsible for devastating ...

A new article details a research breakthrough that provides a promising starting point for scientists to create drugs that can cure C. diff -- a virulent health care-associated infection that causes ...

Clostridium difficile infection is the most common cause of antibiotic-associated diarrhea in developed countries. Researchers have discovered how the C. diff toxin B recognizes the human Frizzled ...

Clinical findings shed more light on toxins produced by C. diff A team from Nashville, Tenn.-based VanderbiltUniversityMedicalCenter has teased out new secrets from Clostridium difficile, the ...

On September 29, 2017, the U.S. Environmental Protection Agency (EPA) announced the availability of two final test method Standard Operating Procedures (SOP) for evaluating the efficacy of ...

A new study, led by researchers from the University of California, Irvine (UCI), uncovers the long-sought-after, three-dimensional structure of a toxin primarily responsible for devastating ...

CHELMSFORD, Mass., Nov. 28, 2018 /PRNewswire/ -- First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive, and cost-effective diagnostic tests for ...

Dear Dr. Roach: I had two previous episodes of C. diff and was treated with vancomycin. My stool tests the first time were negative. Recently, I got the same symptoms, and the doctor did a stool test ...

Please provide your email address to receive an email when new articles are posted on . More patients in the bezlotoxumab group experienced recurrence vs. the placebo group (13% vs. 3%). Steroid use ...